Match!
Hamzah Abu-Sbeih
University of Texas MD Anderson Cancer Center
79Publications
6H-index
153Citations
Publications 82
Newest
Source
#1Hamzah Abu-SbeihH-Index: 6
#2Faisal S. AliH-Index: 4
Last.Yinghong WangH-Index: 9
view all 6 authors...
Source
PURPOSEThe risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI advers...
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 6
#2Tenglong Tang (CSU: Central South University)H-Index: 2
Last.Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 9
view all 9 authors...
Immune checkpoint inhibitor (ICI)-induced pancreatic injury (ICIPI) is not well documented in the literature. We aimed to describe the clinical characteristics and outcomes of patients who developed ICIPI. We reviewed the medical records of consecutive patients who had a confirmed diagnosis of ICIPI (Common Terminology Criteria for Adverse Events grade ≥ 3 lipase elevation with or without clinical symptoms) from April 2011 through April 2018. Among the 2,279 patients received ICI and had lipase ...
5 CitationsSource
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 6
#2Cynthia Nguyen Tran (BCM: Baylor College of Medicine)H-Index: 1
Last.Yinghong Wang (BCM: Baylor College of Medicine)H-Index: 9
view all 8 authors...
Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune-mediated adverse events can complicate ICI treatment. Acute cholecystitis in patients receiving ICI therapy has not been characterized. We aimed to describe the clinical features of patients who developed ICI-related cholecystitis. We evaluated a case series of patients at a tertiary cancer center who received ICI therapy and developed cholecystitis, diagnosed by clinical presentation and diagnost...
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 6
#2Faisal S. Ali (University of Texas MD Anderson Cancer Center)H-Index: 4
Last.Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 9
view all 12 authors...
Background Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in patients who do not respond to steroids. We assessed the effect of early SIT introduction and number of SIT infusions on clinical outcomes.
4 CitationsSource
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 6
#2Lauren Nicholas Herrera (BCM: Baylor College of Medicine)
Last.Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 9
view all 8 authors...
The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI) therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic therapy,especially that with anaerobic activity, has profound effects on the gut microbiome. Therefore, we sought to assess the effect of antibiotics on the development of IMDC. Patients who received ICI therapy from January 2016 to January 2018 were examined retrospectively. A Cox regression model was used to assess factors associate...
Source
Source
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 6
#2Faisal S. Ali (St. Joseph Hospital)H-Index: 4
Last.Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 9
view all 19 authors...
PURPOSEImmune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors for IMDC recurrence after ICI re...
Source
123456789